Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
CompletedOBSERVATIONAL
Enrollment
150
Participants
Timeline
Start Date
July 31, 2014
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
Conditions
Multiple Sclerosis
Trial Locations (1)
14203
Buffalo Neuroimaging Analysis Center, Buffalo
All Listed Sponsors
collaborator
Teva Pharmaceuticals USA
INDUSTRY
lead
University at Buffalo
OTHER
NCT02308670 - Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter